Cargando…
Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpos...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947521/ https://www.ncbi.nlm.nih.gov/pubmed/31756992 http://dx.doi.org/10.3390/jcm8122027 |
_version_ | 1783485570669871104 |
---|---|
author | De Maré, Annelies Verhulst, Anja Cavalier, Etienne Delanaye, Pierre Behets, Geert J. Meijers, Bjorn Kuypers, Dirk D’Haese, Patrick C. Evenepoel, Pieter |
author_facet | De Maré, Annelies Verhulst, Anja Cavalier, Etienne Delanaye, Pierre Behets, Geert J. Meijers, Bjorn Kuypers, Dirk D’Haese, Patrick C. Evenepoel, Pieter |
author_sort | De Maré, Annelies |
collection | PubMed |
description | Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpose, in this study we investigate the extent to which circulating sclerostin, skeletal sclerostin expression, bone histomorphometric parameters, and serum markers of bone metabolism associate with each other. Bone biopsies and serum samples were collected in a cohort of 68 end-stage kidney disease (ESKD) patients. Serum sclerostin levels were measured using 4 different commercially available assays. Skeletal sclerostin expression was evaluated on immunohistochemically stained bone sections. Quantitative bone histomorphometry was performed on Goldner stained tissue sections. Different serum markers of bone metabolism were analyzed using in-house techniques or commercially available assays. Despite large inter-assay differences for circulating sclerostin, results obtained with the 4 assays under study closely correlated with each other, whilst moderate significant correlations with skeletal sclerostin expression were also found. Both skeletal and circulating sclerostin negatively correlated with histomorphometric bone and serum parameters reflecting bone formation and turnover. In this study, the unique combined evaluation of bone sclerostin expression, bone histomorphometry, bone biomarkers, and serum sclerostin levels, as assessed by 4 different assays, demonstrated that sclerostin may qualify as a clinically relevant marker of disturbed bone metabolism in ESKD patients. |
format | Online Article Text |
id | pubmed-6947521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69475212020-01-13 Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease De Maré, Annelies Verhulst, Anja Cavalier, Etienne Delanaye, Pierre Behets, Geert J. Meijers, Bjorn Kuypers, Dirk D’Haese, Patrick C. Evenepoel, Pieter J Clin Med Article Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpose, in this study we investigate the extent to which circulating sclerostin, skeletal sclerostin expression, bone histomorphometric parameters, and serum markers of bone metabolism associate with each other. Bone biopsies and serum samples were collected in a cohort of 68 end-stage kidney disease (ESKD) patients. Serum sclerostin levels were measured using 4 different commercially available assays. Skeletal sclerostin expression was evaluated on immunohistochemically stained bone sections. Quantitative bone histomorphometry was performed on Goldner stained tissue sections. Different serum markers of bone metabolism were analyzed using in-house techniques or commercially available assays. Despite large inter-assay differences for circulating sclerostin, results obtained with the 4 assays under study closely correlated with each other, whilst moderate significant correlations with skeletal sclerostin expression were also found. Both skeletal and circulating sclerostin negatively correlated with histomorphometric bone and serum parameters reflecting bone formation and turnover. In this study, the unique combined evaluation of bone sclerostin expression, bone histomorphometry, bone biomarkers, and serum sclerostin levels, as assessed by 4 different assays, demonstrated that sclerostin may qualify as a clinically relevant marker of disturbed bone metabolism in ESKD patients. MDPI 2019-11-20 /pmc/articles/PMC6947521/ /pubmed/31756992 http://dx.doi.org/10.3390/jcm8122027 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Maré, Annelies Verhulst, Anja Cavalier, Etienne Delanaye, Pierre Behets, Geert J. Meijers, Bjorn Kuypers, Dirk D’Haese, Patrick C. Evenepoel, Pieter Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
title | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
title_full | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
title_fullStr | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
title_full_unstemmed | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
title_short | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
title_sort | clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947521/ https://www.ncbi.nlm.nih.gov/pubmed/31756992 http://dx.doi.org/10.3390/jcm8122027 |
work_keys_str_mv | AT demareannelies clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT verhulstanja clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT cavalieretienne clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT delanayepierre clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT behetsgeertj clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT meijersbjorn clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT kuypersdirk clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT dhaesepatrickc clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease AT evenepoelpieter clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease |